Forest Labs files law suit against several drugmakers for Namenda XR patent infringement

2 February 2014

US drugmaker Forest Laboratories (NYSE:FRX), together with Merz Pharma and Adamas Pharmaceuticals, has filed a law suit for infringement of patents related to its dementia and Alzheimer’s disease drug Namenda XR (memantine).

The suit was filed in the US District Court for the District of Delaware against several companies for infringement of some or all of the drug’s patents. The defendants named in the law suit include Sun Pharma Global FZE, Teva Pharmaceuticals USA Inc, Wockhardt Bio AG and related companies and subsidiaries.

Forest received notification from these companies that they had filed Abbreviated New Drug Applications with Paragraph IV certifications seeking approval to market generic versions of Namenda XR before the expiration of some or all of the patents. The law suit was commenced before the expiration of 45 days from the date of receipt of each notification letter, which triggered an automatic stay of approval of the applicable ANDAs that expires no earlier than June 2016 (unless the court issues a decision adverse to Forest, Merz, and Adamas earlier).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK